SRR12696786
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- DNA_REPAIR+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V2+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ADIPOGENESIS+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- HEDGEHOG_SIGNALING+0.300
- HEME_METABOLISM+0.300
Top 10 suppressed
- KRAS_SIGNALING_DN-0.300
- PANCREAS_BETA_CELLS-0.300
- ALLOGRAFT_REJECTION-0.200
- APICAL_SURFACE-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- COMPLEMENT-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- IL6_JAK_STAT3_SIGNALING-0.100
- INTERFERON_ALPHA_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R205 | — | — | 0.856 |
| 2 | ERR2598070 | fetal | fetal | 0.850 |
| 3 | 5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4 | — | — | 0.838 |
| 4 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.831 |
| 5 | TCGA-FD-A6TH-01A-11R-A32O-07 | — | — | 0.826 |
| 6 | SRR12696801 | — | — | 0.824 |
| 7 | SRR934967 | — | — | 0.819 |
| 8 | MNG252 | — | — | 0.817 |
| 9 | TCGA-BT-A20U-01A-11R-A14Y-07 | — | — | 0.815 |
| 10 | B7B9B5C1-C11D-47B8-B2F8-A5660AB961C1 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |